FOLFOX regimen: Clinical Trials

16 trials of FOLFOX regimen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 6 unknown, 2 active not recruiting, 1 suspended. 16 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 6, Unknown 6, Active not recruiting 2, Suspended 1, Terminated 1
Phase 23Completed 1, Suspended 1, Unknown 1

Follow FOLFOX regimen: new trials by email Literature Review of FOLFOX regimen trials Research Report on FOLFOX regimen

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test
Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer
Phase 3Active not recruitingUNICANCER24502026-07-202026-07-22
Immunotherapy for Advanced Liver Cancer
AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma
Phase 2 / Phase 3SuspendedMirror Biologics, Inc.1502023-08-012025-10-23
Immunosurveillance for Metastatic Colorectal Cancer
Adenorine, Placebo, FOLFOX regimen - Monitoring, Immunologic
Phase 2 / Phase 3CompletedMIPO Clinic1872022-07-152026-06-29
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
FOLFOX regimen, Panitumumab, Bevacizumab - Colorectal Cancer
Phase 3Active not recruitingSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)4192018-10-152024-10-21
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
FOLFOX regimen, Sorafenib 200Mg Tab - Liver Cancer, Hepatic Carcinoma
Phase 3CompletedSun Yat-sen University2622017-03-012020-12-16
Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy
FOLFOX regimen, HD6610 Granule, HD6610 Granule placebo - Peripheral Neuropathy
Phase 2 / Phase 3UnknownJiangsu Province Hospital of Traditional Chinese Medicine642015-08-012015-12-02
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
bevacizumab, cetuximab, FOLFIRI regimen - Colorectal Cancer
Phase 3TerminatedAlliance for Clinical Trials in Oncology3402010-08-012024-12-27
Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer
FOLFOX regimen, CAPOX - Colorectal Cancer
Phase 3UnknownGERCOR - Multidisciplinary Oncology Cooperative Group20002009-05-122023-09-29
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Panitumumab, FOLFOX regimen - Metastatic Colorectal Cancer
Phase 3CompletedAmgen11832006-08-012022-11-07
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
FOLFOX regimen, capecitabine, fluorouracil - Colorectal Cancer
Phase 3CompletedMedical Research Council4602003-09-012021-09-27
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
FOLFOX regimen, fluorouracil, leucovorin calcium - Colorectal Cancer
Phase 3UnknownSanofi2000-10-012014-01-06
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
FOLFOX regimen, fluorouracil, leucovorin calcium - Colorectal Cancer, Metastatic Cancer
Phase 3UnknownEuropean Organisation for Research and Treatment of Cancer - EORTC2000-09-012011-04-18
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
FOLFIRI regimen, FOLFOX regimen, fluorouracil - Colorectal Cancer
Phase 3CompletedMedical Research Council2000-05-012013-12-19
Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
FOLFOX regimen, fluorouracil, leucovorin calcium - Colorectal Cancer
Phase 3UnknownGERCOR - Multidisciplinary Oncology Cooperative Group2000-01-012009-01-13
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
FOLFOX regimen, fluorouracil, leucovorin calcium - Colorectal Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC5541998-03-012012-07-02
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
FOLFIRI regimen, FOLFOX regimen, fluorouracil - Colorectal Cancer
Phase 3UnknownGERCOR - Multidisciplinary Oncology Cooperative Group1091998-01-012009-01-13

Conditions studied

Colorectal Neoplasms (14)  ·  Colonic Neoplasms (9)  ·  Rectal Neoplasms (7)  ·  Carcinoma, Hepatocellular (2)  ·  Liver Neoplasms (2)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Peripheral Nervous System Diseases (1)

Sponsors

GERCOR - Multidisciplinary Oncology Cooperative Group (3)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Medical Research Council (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Amgen (1)  ·  Jiangsu Province Hospital of Traditional Chinese Medicine (1)  ·  MIPO Clinic (1)  ·  Mirror Biologics, Inc. (1)  ·  Sanofi (1)  ·  Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (1)  ·  Sun Yat-sen University (1)  ·  UNICANCER (1)

Countries

France (6)  ·  United Kingdom (3)  ·  Austria (2)  ·  Belgium (2)  ·  Canada (2)  ·  China (2)  ·  Germany (2)  ·  Italy (2)  ·  Norway (2)  ·  Portugal (2)  ·  Sweden (2)  ·  United States (2)  ·  Australia (1)  ·  Greece (1)  ·  Hong Kong (1)

Top investigators

Aimery de Gramont, MD (2)  ·  Matthew T. Seymour, MA, MD, FRCP (2)  ·  Alexander Stojadinovic, MD (1)  ·  Alfredo Carrato, MD, PhD (1)  ·  Bernard Nordlinger, MD (1)  ·  Euan T. Walpole, MD (1)  ·  Francis Levi, MD, PhD (1)  ·  Gareth Griffiths (1)  ·  Huo JieGe, M.D. (1)  ·  John N. Primrose, MD (1)  ·  Mace L. Rothenberg, MD, FACP (1)  ·  Philippe Rougier, MD (1)  ·  Thierry Andre, MD (1)

Results publications

PMID 16877722, PMID 17630037, PMID 18358928, PMID 19554377, PMID 19858398, PMID 19884549, PMID 21570111, PMID 21859417, PMID 22070868, PMID 22314329, PMID 24120480, PMID 26049686, PMID 26342674, PMID 27843597, PMID 28449055, PMID 29620995, PMID 29627309, PMID 30019318, PMID 30614531, PMID 30679026, PMID 31378656, PMID 31515083, PMID 32167864, PMID 34905388, PMID 36306483, PMID 36606664, PMID 39889251, PMID 39903903, PMID 40436447

NIH funding

2009 (1)